Ependymomas

Also known as: Ependymoma

DrugDrug NameDrug Description
DB00262CarmustineA cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
DB09054IdelalisibIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
DrugDrug NamePhaseStatusCount
DB00853Temozolomide0Withdrawn1
DB00531Cyclophosphamide1Recruiting1
DB00260Cycloserine1Completed1
DB00544Fluorouracil1Completed1
DB00724Imiquimod1Completed1
DB12827Indoximod1Recruiting1
DB00877Sirolimus1Active Not Recruiting1
DB00853Temozolomide1Completed1
DB00853Temozolomide1Recruiting1
DB07232Veliparib1Completed1
DB00112Bevacizumab2Recruiting1
DB00958Carboplatin2Recruiting1
DB00958Carboplatin2Terminated1
DB00530Erlotinib2Recruiting1
DB00530Erlotinib2Terminated1
DB09150Fludeoxyglucose F-182Recruiting1
DB05036Grn163l2Completed1
DB00134L-Methionine2Recruiting1
DB09035Nivolumab2Recruiting1
DB00642Pemetrexed2Completed1
DB11689Selumetinib2Recruiting1
DB00853Temozolomide2Recruiting1
DB08881Vemurafenib2Recruiting1
DB00958Carboplatin2 / 3Active Not Recruiting1
DB00773Etoposide2 / 3Active Not Recruiting1
DB00853Temozolomide2 / 3Active Not Recruiting1
DB04572Thiotepa2 / 3Active Not Recruiting1
DB12902Trofosfamide2 / 3Active Not Recruiting1
DB00724ImiquimodNot AvailableRecruiting1